Synbio Tech (ROCO:1295) EBIT: NT$215 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:1295 Synbio Tech Inc ROCO:1295
44 GF Score
Price NT$50.40
! 10 Warning Signs
View Full Analysis

What is Synbio Tech EBIT?

Synbio Tech ROCO:1295 -0.40% 44 EBIT is NT$215 Mil as of Dec. 2025. GuruFocus rates ROCO:1295 with a GF Score™ of 44/100. The stock has 10 warning signs investors should review.

Synbio Tech's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$49 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$215 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Synbio Tech's annualized ROC % for the quarter that ended in Dec. 2025 was 5.18%. Synbio Tech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 9.11%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Synbio Tech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 7.81%.

Synbio Tech  (ROCO:1295) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Synbio Tech's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=133.464 * ( 1 - 1.44% )/( (2409.709 + 2673.469)/ 2 )
=131.5421184/2541.589
=5.18 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2852.019 - 198.648 - ( 402.351 - max(0, 528.677 - 772.339+402.351))
=2409.709

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3085.253 - 281.478 - ( 376.225 - max(0, 639.769 - 770.075+376.225))
=2673.469

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Synbio Tech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=197.296/( ( (1926.625 + max(146.09, 0)) + (2170.633 + max(88.372, 0)) )/ 2 )
=197.296/( ( 2072.715 + 2259.005 )/ 2 )
=197.296/2165.86
=9.11 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(77.342 + 259.104 + 30.089) - (198.648 + 0 + 21.797)
=146.09

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(111.183 + 237.47 + 41.074) - (281.478 + 0 + 19.877)
=88.372

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Synbio Tech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=215.066/2753.036
=7.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synbio Tech EBIT Related Terms

Synbio Tech EBIT Historical Data

* Premium members only.

The historical data trend for Synbio Tech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synbio Tech EBIT Chart

Synbio Tech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 196.00 123.39 153.66 240.30 215.07

Synbio Tech Quarterly Data
Dec20 Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.44 51.67 75.69 38.38 49.32

ROCO:1295 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Synbio Tech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synbio Tech EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synbio Tech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Synbio Tech's EV-to-EBIT falls into.


ROCO:1295
44GF Score
Synbio Tech Inc ROCO:1295
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Synbio Tech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$215 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$215 Mil mean?
Synbio Tech (ROCO:1295) has a EBIT of NT$215 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Synbio Tech.
Is Synbio Tech's EBIT too high?
Synbio Tech's current EBIT is NT$215 Mil. Overall, Synbio Tech has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Synbio Tech's EBIT compare to VRTX and REGN?
Synbio Tech's EBIT of NT$215 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Synbio Tech. Synbio Tech's current EBIT is NT$215 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synbio Tech stock overvalued right now?
Synbio Tech (ROCO:1295) has a current EBIT of NT$215 Mil. The current EBIT is NT$215 Mil. Synbio Tech's overall GF Score™ is 44/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Synbio Tech (ROCO:1295), the current EBIT is NT$215 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Synbio Tech Business Description

Address No.82, Beiling 6th Road, Luzhu District, Kaohsiung, TWN, 821
Synbio Tech Inc focus on functional research and manufacturing of probiotics for human health and economic animals. It has two reportable segments, Taiwan and Mainland China Segment to engage in the production and R&D technologies of the Taiwan Segment, including the production and sales of concentrated fermentation liquid, lactobacillus plantarum solid drinks, and lactobacillus plantarum granules for animal husbandry. It generates majority of revenue from Taiwan segment includes production and sale of lactobacillus plantarum powder, lactobacillus plantarum fermentation derivative products, probiotics dietary supplements, probiotics products for pets and economic animals, and probiotics products. It has presence in Taiwan, China, Southeast Asia, and Others.
44GF Score

Get the complete analysis for ROCO:1295

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$50.40
Price